臨床研究等提出・公開システム

Surveillance of ischemic stroke recurrence after prescription of EFIENT tablets (prasugrel)-JMDC Cohort Study-

Surveillance of ischemic stroke recurrence after prescription of EFIENT tablets (prasugrel)-JMDC Cohort Study-

Tanabe Hirokazu

Daiichi Sankyo Co.,Ltd.

3-5-1,Nihonbashi Honcho,Chuo-ku,Tokyo

contact_gpsp@daiichisankyo.co.jp

Contact for GPSP

Daiichi Sankyo Co.,Ltd.

3-5-1,Nihonbashi Honcho,Chuo-ku,Tokyo

+81-362251059

contact_gpsp@daiichisankyo.co.jp

Not Recruiting

Jan. 01, 2005

Observational

1) Patients who have prescription of prasugrel or clopidogrel within the enrollment period (December 24, 2021 to September 23, 2024). The cohort entry date: first prescription date of prasugrel or clopidogrel within the enrollment period.
2) Patients with acute ischemic stroke treated in hospital have diagnosis of atherothrombotic stroke or lacunar stroke during the past 30 days from the cohort entry date.
3) Patients who have risk factors for ischemic stroke recurrence.
4) The month 90 days prior to the cohort entry date is in the month following the observation start date (Look back period).

1) Patients who have prescription of prasugrel or clopidogrel in the look back period.
2) No medical records from the day after the cohort entry date.
3) Patients who have prescriptions of prasugrel and clopidogrel on the cohort entry date.

Both

Ischemic stroke

Ischemic stroke recurrence

No

none